Last reviewed · How we verify
NCT05450822: BDE
Precision Medicine in the Treatment of Epilepsy
trial testing Levetiracetam in Epilepsy in 550 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Gitte Moos Knudsen |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 550 |
| Start date | 18 February 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2031 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Levetiracetam (levetiracetam) — full drug profile →
- Levetiracetam Tablets — full drug profile →
- Lamotrigine tablet — full drug profile →
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
Gitte Moos Knudsen — full company profile →
Who can join
Adults 16 to 55, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary objectives: The purpose of this study is to identify single and composite biomarkers (from neuroimaging, electrophysiological, and non-imaging biological measures), clinical measures (from cognitive, psychometric, and behavioral test scores), and risk/protective factors (e.g., from medical history, socioeconomic status, coping, lifestyle) that can: 1. Predict antiseizure medication (ASM) treatment outcome, psychiatric, cognitive, or behavioral comorbidities, and quality of life in newly diagnosed epilepsy patients (Cohort II-III). 2. Predict a second epileptic seizure/epilepsy diagnosis and behavioral, cognitive, psychiatric dysfunction and quality of life in patients after a first epileptic seizure (Cohort I).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Preclinical validation and kinetic modelling of the SV2A PET ligand [<sup>18</sup>F]UCB-J in mice.
Everix L, Elvas F, Miranda Menchaca A, Khetarpal V, et al · · 2025 · cited 4× · PMID 39628318 · DOI 10.1177/0271678x241304923 -
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [<sup>11</sup>C]UCB-J PET study.
Marstrand-Joergensen MR, Laurell GL, Herrmann S, Nasser A, et al · · 2024 · cited 1× · PMID 38758370 · DOI 10.1007/s00259-024-06759-x -
The BrainDrugs-epilepsy study: A prospective open-label cohort precision medicine study in epilepsy.
Marstrand-Joergensen MR, Dam VH, Vinter K, Ip CT, et al · · 2023 · PMID 40655979 · DOI 10.1016/j.nsa.2023.101136 -
Clinical Trials of Non-Coding RNAs as Diagnostic and Therapeutic Biomarkers for Central Nervous System Injuries.
Wang H, Wang Q, Xiao X, Luo X, et al · · 2023 · PMID 36443964 · DOI 10.2174/1570159x21666221128090025
Verify or expand the search:
- PubMed search for NCT05450822
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Levetiracetam
Trials testing the same drug.
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
- NCT07072624 — Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial) · Phase 4 · recruiting
- NCT07046611 — Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children · Phase 2, PHASE3 · recruiting
- NCT06773364 — Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial · Phase 3 · recruiting
- NCT07052136 — Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus · NA · completed
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Gitte Moos Knudsen trials
Trials by the same sponsor.
- NCT04280055 — Prophylactic Effects of Psilocybin on Chronic Cluster Headache · Phase 1, PHASE2 · terminated
- NCT03576664 — Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans · EARLY_PHASE1 · completed
- NCT03289949 — The Neurobiological Effect of 5-HT2AR Modulation · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05450822 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gitte Moos Knudsen
- Last refreshed: 11 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05450822.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing